Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.
复制标题
DOI：
10.1053/j.gastro.2016.09.047
复制
发表时间：
2017-02
期刊：
影响因子：
29.4
通讯作者：
Rogler G
中科院分区：
文献类型：
--
作者：
Rieder F;Fiocchi C;Rogler G
在过去的10年里，我们已经了解了很多关于炎症性肠病（IBD）患者肠纤维化的发病机制，诊断和管理。就在十年前，肠道狭窄被认为是对抗炎治疗无反应的患者长期炎症的不可避免的后果。IBD相关的纤维化被视为一个不可逆转的过程，经常导致需要手术干预的肠阻塞。由于抗纤维化方法可能变得可用，这种模式已经迅速改变。我们回顾了IBD严重并发症的机制和诊断，以及预测其进展和管理策略的因素。
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases (IBD). Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. IBD-associated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the anti-fibrotic approaches that may become available. We review the mechanisms and diagnosis of this serious complication of IBD, as well as factors that predict its progression and management strategies.
登录
查看更多内容
影响因子：
9.8
作者：
Brand, S;Hofbauer, K;Lohse, P
通讯作者：
Lohse, P
影响因子：
8
作者：
Atreja, Ashish;Aggarwal, Ashish;Shen, Bo
通讯作者：
Shen, Bo
影响因子：
29.4
作者：
Beaugerie, L;Seksik, P;Cosnes, J
通讯作者：
Cosnes, J
影响因子：
4.3
作者：
Allez, Matthieu;Lemann, Marc
通讯作者：
Lemann, Marc
影响因子：
3.9
作者：
Borley, NR;Mortensen, NJM;Warren, BF
通讯作者：
Warren, BF